Esophageal cancer is one of the most aggressive cancers affecting the gastrointestinal tract and is known to have a poor outcome. Approximately 482,300 new cases and 406,800 deaths from esophageal cancer occurred worldwide in 2008 \[[@CR1]\]. In Japan, these numbers were 20,556 and 11,592, respectively \[[@CR2]\].

Esophagectomy is the standard treatment for potentially resectable thoracic esophageal cancer \[[@CR3]\]. It typically consists of transthoracic esophageal resection and transabdominal gastric mobilization for esophageal replacement. However, because it includes a wide surgical excision, esophagectomy is associated with a higher risk of postoperative morbidity and mortality than those in other cancer surgeries \[[@CR4], [@CR5]\]. Postoperative pulmonary complications (PPCs) are the most common causes of serious morbidity after esophagectomy and can result in a poor prognosis in esophagectomized patients \[[@CR6]--[@CR8]\]. Therefore, PPC prevention is crucial to improve the survival of patients with esophageal cancer.

Thoracoscopic esophagectomy was first introduced in 1992 \[[@CR9]\] and has been extensively performed in recent years \[[@CR10]\]. This approach minimizes the extent of chest trauma. Several studies, including those from our group, have reported that it decreases PPC frequency \[[@CR11]--[@CR14]\]. However, it remains unclear whether PPC frequency is further decreased by combining this thoracoscopic esophagectomy with laparoscopic gastric mobilization because previous prospective studies have only evaluated the combined impact of the two approaches \[[@CR13], [@CR14]\]. The present study uses data from our prospective multicenter trial, the Japan Clinical Oncology Group Study 0502 (JCOG0502), to determine the effect of laparoscopy on the prevention of PPCs after thoracoscopic esophagectomy and the factors playing a role in this prevention.

Materials and methods {#Sec1}
=====================

Study design and patient selection {#Sec2}
----------------------------------

JCOG0502 is a four-arm prospective study comparing esophagectomy with definitive chemo-radiotherapy for T1bN0 cancers and includes randomized and patient preference arms. Patients were assigned for randomization if they had no strong preference and were then randomly allocated to one of the two treatments (Fig. [1](#Fig1){ref-type="fig"}). However, if patients had a strong preference and refused randomization, they were allocated to the arm with their preferred treatment. Written informed consent was obtained from all enrolled patients. The study protocol was approved by the Clinical Trial Review Committee of the JCOG and by the review boards of all the participating institutions. The trial was registered with UMIN-CTR ([www.umin.ac.jp/ctr/](http://www.umin.ac.jp/ctr/)) (registration number: UMIN000000551). Patient accrual for this study has been completed. The primary endpoint is overall survival in the randomized arm, which will be analyzed in 2018. The key eligibility criteria for JCOG0502 were as follows: age between 20 and 75 years, diagnosis of histologically proven clinical stage IA (T1bN0) squamous cell carcinoma, adenosquamous cell carcinoma, or basaloid cell carcinoma in the thoracic esophagus according to the American Joint Committee on Cancer Staging Manual (7th edition), and performance status 0--1 according to the Eastern Cooperative Oncology Group. The major exclusion criteria were as follows: double primary cancer, uncontrolled diabetes, recent myocardial infarction (≤3 months), unstable angina, chronic obstructive pulmonary disease, pulmonary fibrosis, and heart failure.Fig. 1Flow diagram for the Japan Clinical Oncology Group (JCOG) 0502 study, with the present study highlighted in *light blue* (Color figure online)

Operative methods {#Sec3}
-----------------

After the patients were allocated to the surgery arms, subtotal esophagectomy with lymphadenectomy was performed without preoperative chemotherapy and/or radiotherapy. The use of thoracoscopy and/or laparoscopy was decided at the surgeon's discretion without any intention to compare these approaches, regardless of randomization or patient preference. Thoracoscopic esophagectomy was performed in the prone or lateral decubitus position according to the standards of each participating institution. In case of laparoscopic surgery, a minilaparotomy was made through which gastric conduits were created extracorporeally and specimens were removed. It could also be used as a hand-access port. Patients with upper thoracic disease underwent three-field lymphadenectomy, whereas those with mid- or lower thoracic disease underwent either two- or three-field lymphadenectomy at the surgeon's discretion.

Definitions and statistical methods {#Sec4}
-----------------------------------

PPCs were defined as one or more of the following postoperative morbidities grade ≥2 as per Common Terminology Criteria for Adverse Events (CTCAE) v3.0: pneumonia, atelectasis, and acute respiratory distress syndrome. Other postoperative complications were defined as adverse events of grade ≥2 as per CTCAE v3.0. Postoperative mortality was defined as postoperative death within 30 days due to any cause, or death during the same hospital admission. Preoperative laboratory data were divided into two categories based on the median values. To compare open and thoracoscopic/laparoscopic surgery groups, the Wilcoxon rank-sum test and Fisher's exact test were used for continuous data and categorical data, respectively. Multivariable analysis included logistic regression without variable selection as well as stepwise variable selection (with *α* = 0.2 for including and/or retaining a variable in the model). Baseline characteristics, preoperative laboratory data, and operative factors were included as explanatory variables in the multivariable analyses. The level of significance was set at a two-sided *p* value of \<0.05. All analyses were performed using SAS software, v9.2 (SAS Institute Inc., Cary, NC) at the JCOG Data Center. The data presented in this article include those up to June 2015.

Results {#Sec5}
=======

A total of 379 patients with clinical stage IA (T1bN0) thoracic esophageal cancer from 37 institutions were enrolled in JCOG0502 between December 2006 and February 2013. Excluding one patient who withdrew consent postoperatively, 210 of 379 patients underwent transthoracic esophagectomy (Fig. [1](#Fig1){ref-type="fig"}). These patients were enrolled from 30 institutions, and the median number of patients from each institution was 5 (range, 1--28). Gastric pull-up reconstruction was performed in the majority of patients (*n* = 206) with the colon being used as a conduit in the remaining patients (*n* = 4). Cervical anastomosis was performed in 198 patients, whereas intrathoracic anastomosis was performed in 12 patients. Of the 210 patients, 102 underwent thoracotomic esophagectomy with laparotomy, 7 underwent thoracotomy with laparoscopy, 43 underwent thoracoscopy with laparotomy, and 58 underwent thoracoscopy with laparoscopy (Fig. [1](#Fig1){ref-type="fig"}).

Impact of thoracoscopy on PPC prevention {#Sec6}
----------------------------------------

First, we compared thoracotomy (*n* = 109) and thoracoscopy (*n* = 101) to confirm the effect of thoracoscopic approach on PPC prevention. As shown in Table [1](#Tab1){ref-type="table"}, there were no significant differences in the baseline characteristics of patients between the two approaches. Operative data showed that the thoracoscopic approach reduced blood loss but prolonged the operating time. Postoperatively, patients undergoing thoracoscopy had a lower PPC frequency than those undergoing thoracotomy \[thoracoscopy 16 (15.8%), thoracotomy 33 (30.3%); *p* = 0.015\], particularly atelectasis \[thoracoscopy 11 (10.9%), thoracotomy 24 (22.0%); *p* = 0.041\] (Table [2](#Tab2){ref-type="table"}). There were no significant differences in the incidences of other complications and postoperative stay duration between the two approaches.Table 1Baseline characteristics and operative factorsA: Thoracotomy (*n* = 109)B: Thoracoscopy (*n* = 101)A vs BC vs DLaparotomy (*n* = 102)Laparoscopy (*n* = 7)C: Laparotomy (*n* = 43)D: Laparoscopy (*n* = 58)*n* (%)*n* (%)*n* (%)*n* (%)*p* ^a^*p* ^a^Baseline characteristics Age (years) Median (range)61.5 (41--75)67 (58--72)63 (52--75)62.5 (48--75)0.5220.765 Gender  Male87 (85.3)6 (85.7)33 (76.7)49 (84.5)0.462^b^0.441^b^  Female15 (14.7)1 (14.3)10 (23.3)9 (15.5) Performance status^c^  0102 (100)7 (100)43 (100)57 (98.3)0.481^b^1.00^b^  10 (0)0 (0)0 (0)1 (1.7) Body mass index  Median (range)22.4 (13.4--28.9)20.2 (18.6--26.0)22.9 (17.1--28.4)22.5 (18.3--28.3)0.9340.718 Preoperative PaO~2~^d^  Median (range)87.7 (70.0--116.7)89.6 (73.6--114.0)86.0 (71.0--112.0)88.2 (71.1--155.0)0.9630.163 Tumor location  Upper thoracic10 (9.8)1 (14.3)6 (14.0)9 (15.5)0.183^b^1.00^b^  Mid-thoracic63 (61.8)3 (42.9)29 (67.4)38 (65.5)  Lower thoracic29 (28.4)3 (42.9)8 (18.6)11 (19.0) Tumor size  ≤4 cm72 (70.6)4 (57.1)29 (67.4)41 (70.7)1.00^b^0.828^b^  \>4 cm30 (29.4)3 (42.9)14 (32.6)17 (29.3)Operative factors Body position during thoracoscopy  ProneNANA17 (39.5)23 (39.7)NA0.990^b^  Lateral decubitusNANA26 (60.5)35 (60.3) Lymphadenectomy  Two-field37 (36.3)4 (57.1)17 (39.5)23 (39.7)0.779^b^1.00^b^  Three-field65 (63.7)3 (42.9)26 (60.5)35 (60.3) Lymph nodes harvested  Median (range)48 (19--120)44 (28--54)53 (21--120)57 (18--120)0.0630.690 Blood loss (mL)  Median (range)448 (80--1833)240 (45--350)351 (0--4225)283.5 (10--2020)\<0.0010.282 Operating time (min)  Median (range)405 (222--638)338 (280--420)476 (310--791)533.5 (355--871)\<0.0010.014*NA* not applicable^a^Wilcoxon rank-sum test^b^Fisher's exact test^c^Eastern Cooperative Oncology Group performance status^d^Partial pressure of O~2~ in arterial blood Table 2Postoperative pulmonary complications and other outcomesA: Thoracotomy (*n* = 109)B: Thoracoscopy (*n* = 101)A vs BC vs DLaparotomy (*n* = 102)Laparoscopy (*n* = 7)C: Laparotomy (*n* = 43)D: Laparoscopy (*n* = 58)*n* (%)*n* (%)*n* (%)*n* (%)*p* ^a^*p* ^a^Pulmonary complications (PPCs)32 (31.4)1 (14.3)7 (16.3)9 (15.5)0.0151.00 Pneumonia17 (16.7)1 (14.3)2 (4.7)6 (10.3)0.0630.461 Atelectasis23 (22.5)1 (14.3)6 (14.0)5 (8.6)0.0410.521 ARDS^b^0 (0)0 (0)0 (0)1 (1.7)0.4811.00Recurrent nerve palsy16 (15.7)1 (14.3)6 (14.0)9 (15.5)1.001.00Anastomotic leak14 (13.7)1 (14.3)2 (4.7)5 (8.6)0.1200.696Postoperative mortality1 (1.0)0 (0)0 (0)1 (1.7)1.001.00Postoperative stay duration (days) Median (range)22 (10--162)17 (17--32)22 (9--114)24 (12--185)0.472^c^0.514^ca^Fisher's exact test^b^Acute respiratory distress syndrome^c^Wilcoxon rank-sum test

Impact of laparoscopy on PPC prevention {#Sec7}
---------------------------------------

Next, we determined whether PPC frequency was further decreased when combined with laparoscopy. Among the 101 patients who underwent thoracoscopic esophagectomy, 43 underwent laparotomy and 58 underwent laparoscopy (Fig. [1](#Fig1){ref-type="fig"}). As shown in Table [1](#Tab1){ref-type="table"}, there were no significant differences in the baseline characteristics of the patients between the two approaches. Operative data showed that laparoscopy prolonged the operating time. Postoperatively, there were no significant differences in PPC frequency \[laparoscopy 9 (15.5%), laparotomy 7 (16.3%); *p* = 1.00\] and other postoperative complications/outcomes between the two approaches (Table [2](#Tab2){ref-type="table"}).

Among the 109 patients who underwent thoracotomic esophagectomy, PPCs occurred in 32 patients (31.4%) in the laparotomy group and in 1 patient (14.3%) in the laparoscopy group. There was no significant difference between the two groups (*p* = 0.673).

Preventive factors for PPCs {#Sec8}
---------------------------

Finally, we comprehensively analyzed the data from all 210 patients to determine if laparoscopy could aid in the prevention of PPCs. In univariable analysis, both thoracoscopy (shown above) and less blood loss (\< 350 mL 16.3%, ≥350 mL 30.2%; *p* = 0.022) were associated with PPC prevention (Table [3](#Tab3){ref-type="table"}), whereas laparoscopy showed a borderline significant reduction in PPC frequency (laparoscopy 15.4%, laparotomy 26.9%; *p* = 0.079). Multivariable analysis identified both thoracoscopy (Odds ratio, 0.40; 95% confidence interval, 0.16--1.04; *p* = 0.059) and preoperative partial pressure of O~2~ (PaO~2~) in arterial blood (Odds ratio, 0.50; 95% confidence interval, 0.24--1.02; *p* = 0.057) as preventive factors with borderline significance. Stepwise regression analysis showed that both thoracoscopy (Odds ratio, 0.46; 95% confidence interval, 0.23--0.92; *p* = 0.028) and less blood loss (Odds ratio, 0.50; 95% confidence interval, 0.25--0.99; *p* = 0.048) were associated with PPC prevention.Table 3Preventive factors for pulmonary complicationsTotalUnivariable analysisMultivariable analysis w/o variable selectionMultivariable analysis with stepwise selection*nn* (%)*p* ^a^OR (95% CI)^b^*p* ^c^OR (95% CI)^b^*p* ^c^Baseline characteristics Age (years)  \<6512929 (22.5)0.7391  ≥658120 (24.7)1.28 (0.60--2.71)0.524 Gender  Female359 (25.7)0.6691  Male17540 (22.9)0.75 (0.27--2.10)0.586 Body mass index  \<2516840 (23.8)0.8401  ≥25429 (21.4)0.63 (0.21--1.60)0.334 Tumor location  Upper thoracic266 (23.1)0.9701  Mid-thoracic13332 (24.1)0.99 (0.33--2.99)0.985  Lower thoracic5111 (21.6)0.76 (0.20--2.91)0.689 Tumor size  ≤4 cm14631 (21.2)0.2911  \>4 cm6418 (28.1)1.48 (0.70--3.13)0.311Preoperative laboratory data WBC count  \<5800/μL10224 (23.5)1.0001  ≥5800/μL10825 (23.1)1.09 (0.50--2.34)0.836 Hemoglobin  \<13.5/12.5^d^ g/dL6716 (23.9)1.0001  ≥13.5/12.5^d^ g/dL14333 (23.1)0.78 (0.35--1.73)0.538 Platelet count  \<22.1 × 10^4^/μL10523 (21.9)0.7441  ≥22.1 × 10^4^/μL10526 (24.8)1.25 (0.62--2.52)0.539 Total protein  \<7.0 g/dL10521 (20.0)0.3281  ≥7.0 g/dL10528 (26.7)1.28 (0.85--3.70)0.497 Total bilirubin  \<0.7 mg/dL10419 (18.3)0.10311  ≥0.7 mg/dL10630 (28.3)1.77 (0.85--3.70)0.1291.77 (0.90--3.52)0.101 Serum creatinine  \<0.77 mg/dL10726 (24.3)0.7471  ≥0.77 mg/dL10323 (22.3)0.86 (0.39--1.88)0.703 PaO~2~^e^  \<87.9 mmHg10529 (27.6)0.19211  ≥87.9 mmHg10520 (19.0)0.50 (0.24--1.02)0.0570.53 (0.27--1.04)0.065Operative factors Thoracic approach  Thoracotomy10933 (30.3)0.01511  Thoracoscopy10116 (15.8)0.40 (0.16--1.04)0.0590.46 (0.23--0.92)0.028 Abdominal approach  Laparotomy14539 (26.9)0.0791  Laparoscopy6510 (15.4)0.90 (0.33--2.44)0.842 Lymphadenectomy  Two-field8119 (23.5)1.0001  Three-field12930 (23.3)0.94 (0.42--2.13)0.887 Blood loss  \<350 mL10417 (16.3)0.02211  ≥350 mL10632 (30.2)1.27 (0.54--2.98)0.5872.01 (1.01--4.03)0.048 Operating time  \<452 min10525 (23.8)1.0001  ≥452 min10524 (22.9)2.00 (0.91--4.39)0.083^a^Fisher's exact test^b^Odds ratio (95% confidence interval)^c^Logistic regression model^d^Cutoff value for male/female patients^e^Partial pressure of O~2~ in arterial blood

Discussion {#Sec9}
==========

The present study demonstrated that the laparoscopic approach had limited effect on PPC prevention after thoracoscopic esophagectomy. To the best of our knowledge, this is only the second study using data from a prospective multicenter trial that evaluated the effect of laparoscopy on PPC prevention after esophagectomy. The first phase III multicenter trial (MIRO trial) was conducted by Mariette et al. \[[@CR15]\]. They reported that laparoscopy decreased PPC frequency to a greater extent than that by laparotomy under the condition of thoracotomy (laparoscopy 17.7%, laparotomy 30.1%; *p* = 0.037) \[[@CR16]\]. This result is similar to that of the present study comparing laparoscopy with laparotomy following thoracotomic esophagectomy (laparoscopy 14.3%, laparotomy 31.4%), although the difference was not significant (*p* = 0.673) due to the lack of power. Therefore, our results are consistent with those of the MIRO trial, and laparoscopy is recommended to prevent PPCs under the condition of thoracotomy.

Another prospective randomized trial (TIME trial) reported that a combination of thoracoscopic and laparoscopic approaches decreased the frequency of pneumonia to a great extent compared with thoracotomy with laparotomy (thoracoscopy--laparoscopy: 9%, thoracotomy--laparotomy: 29%; *p* = 0.005) \[[@CR13]\]. However, the extent to which each minimally invasive approach contributes to this reduction is still unclear. The present study demonstrated that laparoscopy showed a borderline significant reduction in PPC frequency, whereas thoracoscopy showed an independent and significant reduction in PPC frequency. Therefore, it is likely that the impact of thoracoscopy on the prevention of pneumonia in the TIME trial was more than that of laparoscopy.

It is well known that laparoscopic surgery maintains better postoperative respiratory function than open abdominal surgery \[[@CR17], [@CR18]\], thus potentially affecting PPC prevention after thoracoscopic esophagectomy. However, whether laparoscopy contributes to better postoperative respiratory function \[[@CR19], [@CR20]\] and reduction of PPC frequency \[[@CR8], [@CR19], [@CR20]\] remains controversial. In the present study, laparoscopy failed to show any substantial effect on PPC prevention under this condition. We speculated that this is because the preventive effect of thoracoscopy was so dominant that it masked that of laparoscopy. Under the condition of thoracotomy, a laparoscopic approach could potentially have a substantial effect on PPC prevention.

Another possible explanation for laparoscopy failing to show a substantial preventive impact after thoracoscopic esophagectomy is the presence of a minilaparotomy. In the MIRO trial, surgeons created a gastric conduit intracorporeally using a pure laparoscopic approach without any minilaparotomy, and specimens were removed via the thoracotomic incision \[[@CR15]\]. In contrast, gastric conduits in the laparoscopic group of the present study were created extracorporeally through a minilaparotomy, and specimens were removed via this incision. We speculate that the pain and discomfort caused by the minilaparotomy diminished the preventive effect of laparoscopy on PPCs. A laparoscopic approach without minilaparotomy may be required to further decrease PPC frequency after thoracoscopic esophagectomy.

The prone position with artificial pneumothorax is reported to have an advantage over the lateral decubitus position by avoiding total lung collapse, thereby decreasing the incidence of PPCs \[[@CR21]\]. In the present study, the body positions were equally distributed between the laparotomy and laparoscopy groups as shown in Table [1](#Tab1){ref-type="table"}. Therefore, it is not likely that the body position during thoracoscopic esophagectomy affected the results in the present study.

Multivariable analysis in the present study indicated that thoracoscopy and less blood loss were significant PPC preventive factors. It has previously been reported that less blood loss is associated with PPC prevention after esophagectomy \[[@CR7], [@CR22], [@CR23]\]. Total blood loss during surgery is one of the parameters to estimate surgical stress in surgical risk scoring systems \[[@CR24], [@CR25]\], and the calculated risk score is well correlated with the postoperative morbidity and mortality rates after gastrointestinal surgery \[[@CR26]\]. Therefore, it is likely that less blood loss is one of the PPC preventive factors after esophagectomy.

The median body mass index (BMI) in the present study (22.5) was lower than that in trials conducted in Western countries (24.0--25.0) \[[@CR13], [@CR16]\]. It has been reported that patients with a high BMI do not have increased risk of PPCs after esophagectomy compared with those with a normal BMI \[[@CR27], [@CR28]\]. Likewise, the present study showed no significant increase in PPC frequency in the BMI ≥25 group (Table [3](#Tab3){ref-type="table"}). The pneumonia and PPC frequencies in the thoracotomy--laparotomy (control) group were reported to be 29 and 30.1% in the TIME and MIRO trials, respectively \[[@CR13], [@CR16]\], which are comparable with that of the present study (31.4%). Thus, it is not likely that the lower BMI affected the results in the present study.

The present study had some limitations. First, because it was designed as a non-randomized comparison with a limited number of patients, the results may have been affected by patient selection bias and low statistical power. Second, there are omitted preoperative patient variables of pulmonary function tests, smoking history, and comorbidities, which may influence PPC frequency. Third, esophagectomy was only performed for patients with stage IA esophageal cancers. Therefore, the results may not be generalized to advanced esophageal cancers, which require preoperative therapy and more invasive surgical manipulation. Finally, the results may have been influenced by different surgical techniques and perioperative patient care styles because they were carried out depending on the standards of each participating institution.

Our new randomized phase III trial, JCOG1409 (MONET trial), is currently underway to compare the efficacy and safety of thoracoscopic esophagectomy and thoracotomic esophagectomy. In the MONET trial, patients are further stratified based on whether they undergo laparotomy or laparoscopy for gastric mobilization, performed according to the standard of each participating institution \[[@CR29]\]. We expect that the data from JCOG1409 will strengthen the conclusions of the present study.

In conclusion, the present study demonstrated that the thoracoscopic approach and less blood loss were significant factors in the prevention of PPCs after esophagectomy, whereas the laparoscopic approach had minimal effect on the prevention of PPCs after thoracoscopic esophagectomy.
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